Joannie M. Allaire

Joannie M. Allaire

Auto-generated profile, based on publicly available information

Joannie M. Allaire

Affiliation Department of Pediatrics, BC Children’s Hospital, University of British Columbia, Vancouver, British Columbia, Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Trends in Immunology
Verified
Journal Article
Closed access
JAJoannie M. Allaire
Joannie M. Allaire
SCShauna M. Crowley
Shauna M. Crowley
HLHong T. Law
Hong T. Law
SCSun-Young Chang
Sun-Young Chang
HKHyun-Jeong Ko
Hyun-Jeong Ko
BVBruce A Vallance
Bruce A Vallance

1 February 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
BTBoyan K. Tsankov
Boyan K. Tsankov
JAJoannie M. Allaire
Joannie M. Allaire
MIMichael A. Irvine
Michael A. Irvine
ALAlison A. Lopez
Alison A. Lopez
LSLaura J. Sauvé
Laura J. Sauvé
KJKevan Jacobson
Kevan Jacobson
There is limited information on the severity of COVID-19 infection in children with comorbidities. We investigated the effects of pediatric comorbidities on COVID-19 severity by means of a systematic review and meta-analysis of published literature. PubMed, Embase, and Medline databases were searched for publications on pediatric COVID-19 infections published January 1st to October 5th, 2020. Articles describing at least one child with and without comorbidities, COVID-19 infection, and reported outcomes, were included. 42 studies containing 275,661 children without comorbidities and 9,353 children with comorbidities were included. Severe COVID-19 was present in 5.1% of children with comorbidities, and in 0.2% without comorbidities. Random-effects analysis revealed a higher risk of severe COVID-19 among children with comorbidities than for healthy children; relative risk ratio 1.79 (95% CI 1.27 - 2.51;I2 = 94%). Children with underlying conditions also had a higher risk of COVID-19-associated mortality; relative risk ratio 2.81 (95% CI 1.31 - 6.02; I2 = 82%). Children with obesity had a relative risk ratio of 2.87 (95% CI 1.16 - 7.07 I2 = 36%). Children with comorbidities have a higher risk of severe COVID-19 and associated mortality than children without underlying disease. Additional studies are required to further evaluate this relationship.

28 March 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GBGanive Bhinder
Ganive Bhinder
JAJoannie M. Allaire
Joannie M. Allaire
Cyrielle GarciaCyrielle Garcia
Cyrielle Garcia
JLJennifer T. Lau
Jennifer T. Lau
JCJustin M. Chan
Justin M. Chan
BVBruce A Vallance
Bruce A Vallance
Breast milk has many beneficial properties and unusual characteristics including a unique fat component, termed milk fat globule membrane (MFGM). While breast milk yields important developmental benefits, there are situations where it is unavailable resulting in a need for formula feeding. Most formulas do not contain MFGM, but derive their lipids from vegetable sources, which differ greatly in size and composition. Here we tested the effects of MFGM supplementation on intestinal development and the microbiome as well as its potential to protect against Clostridium difficile induced colitis. The pup-in-a-cup model was used to deliver either control or MFGM supplemented formula to rats from 5 to 15 days of age; with mother’s milk (MM) reared animals used as controls. While CTL formula yielded significant deficits in intestinal development as compared to MM littermates, addition of MFGM to formula restored intestinal growth, Paneth and goblet cell numbers, and tight junction protein patterns to that of MM pups. Moreover, the gut microbiota of MFGM and MM pups displayed greater similarities than CTL, and proved protective against C. difficile toxin induced inflammation. Our study thus demonstrates that addition of MFGM to formula promotes development of the intestinal epithelium and microbiome and protects against inflammation.

13 April 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
SCShauna M. Crowley
Shauna M. Crowley
XHXiao Han
Xiao Han
JAJoannie M. Allaire
Joannie M. Allaire
MSMartin Stahl
Martin Stahl
IRIsabella Rauch
Isabella Rauch
BVBruce A Vallance
Bruce A Vallance
We investigated the role of the inflammasome effector caspases-1 and -11 during Salmonella enterica serovar Typhimurium infection of murine intestinal epithelial cells (IECs). Salmonella burdens were significantly greater in the intestines of caspase-1/11 deficient (Casp1/11−/−), Casp1−/− and Casp11−/− mice, as compared to wildtype mice. To determine if this reflected IEC-intrinsic inflammasomes, enteroid monolayers were derived and infected with Salmonella. Casp11−/− and wildtype monolayers responded similarly, whereas Casp1−/− and Casp1/11−/− monolayers carried significantly increased intracellular burdens, concomitant with marked decreases in IEC shedding and death. Pretreatment with IFN-γ to mimic inflammation increased caspase-11 levels and IEC death, and reduced Salmonella burdens in Casp1−/− monolayers, while high intracellular burdens and limited cell shedding persisted in Casp1/11−/− monolayers. Thus caspase-1 regulates inflammasome responses in IECs at baseline, while proinflammatory activation of IECs reveals a compensatory role for caspase-11. These results demonstrate the importance of IEC-intrinsic canonical and non-canonical inflammasomes in host defense against Salmonella. Intestinal epithelial cells (IECs) are located at the interface between the gut lumen and the mucosal immune system and form the first layer of defense against the invasive enteric pathogen Salmonella enterica serovar Typhimurium. To prevent Salmonella, and other pathogens from establishing a foothold in the gut, the host mobilizes the inflammasome to selectively eject infected/compromised IECs from the epithelial layer into the intestinal lumen. This involves the activation of the inflammatory caspases; caspase-1 and -11. The individual contributions of each caspase to intestinal host defense, as well as the importance of IEC-intrinsic inflammasomes have not been previously defined, due to the lack of Casp1−/− mice as well as appropriate IEC-intrinsic defense models. Here, we determined that both caspases contribute to controlling Salmonella pathogen burdens and IEC shedding in the mouse intestine. Caspase-1 appears to play a larger role at baseline since caspase-11 expression must be first induced through proinflammatory signalling. Our data also highlights that IEC-intrinsic caspase activation is sufficient for infection-induced cell shedding and that the intestinal epithelium is a key site for inflammasome-mediated immune defense.

1 March 2018 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
JAJoannie M. Allaire
Joannie M. Allaire
VMVijay Morampudi
Vijay Morampudi
SCShauna Mary Crowley
Shauna Mary Crowley
MSMartin Stahl
Martin Stahl
HYHongbing Yu
Hongbing Yu
BVBruce A Vallance
Bruce A Vallance
Goblet cells (GCs) are the predominant secretory epithelial cells lining the luminal surface of the mammalian gastrointestinal (GI) tract. Best known for their apical release of mucin 2 (Muc2), which is critical for the formation of the intestinal mucus barrier, GCs have often been overlooked for their active contributions to intestinal protection and host defense. In part, this oversight reflects the limited tools available to study their function but also because GCs have long been viewed as relatively passive players in promoting intestinal homeostasis and host defense. In light of recent studies, this perspective has shifted, as current evidence suggests that Muc2 as well as other GC mediators are actively released into the lumen to defend the host when the GI tract is challenged by noxious stimuli. The ability of GCs to sense and respond to danger signals, such as bacterial pathogens, has recently been linked to inflammasome signaling, potentially intrinsic to the GCs themselves. Moreover, further work suggests that GCs release Muc2, as well as other mediators, to modulate the composition of the gut microbiome, leading to both the expansion as well as the depletion of specific gut microbes. This review will focus on the mechanisms by which GCs actively defend the host from noxious stimuli, as well as describe advanced technologies and new approaches by which their responses can be addressed. Taken together, we will highlight current insights into this understudied, yet critical, aspect of intestinal mucosal protection and its role in promoting gut defense and homeostasis.

8 October 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HYHONG BING YU
HONG BING YU
HYHyungjun Yang
Hyungjun Yang
JAJoannie M. Allaire
Joannie M. Allaire
CMCaixia Ma
Caixia Ma
FGFranziska A. Graef
Franziska A. Graef
KJKevan Jacobson
Kevan Jacobson
Group 3 innate lymphoid cells (ILC3s) control the formation of intestinal lymphoid tissues and play key roles in intestinal defense. They express neuropeptide vasoactive intestinal peptide (VIP) receptor 2 (VPAC2), through which VIP modulates their function, but whether VIP exerts other effects on ILC3 remains unclear. We show that VIP promotes ILC3 recruitment to the intestine through VPAC1 independent of the microbiota or adaptive immunity. VIP is also required for postnatal formation of lymphoid tissues as well as the maintenance of local populations of retinoic acid (RA)–producing dendritic cells, with RA up-regulating gut-homing receptor CCR9 expression by ILC3s. Correspondingly, mice deficient in VIP or VPAC1 suffer a paucity of intestinal ILC3s along with impaired production of the cytokine IL-22, rendering them highly susceptible to the enteric pathogen Citrobacter rodentium. This heightened susceptibility to C. rodentium infection was ameliorated by RA supplementation, adoptive transfer of ILC3s, or by recombinant IL-22. Thus, VIP regulates the recruitment of intestinal ILC3s and formation of postnatal intestinal lymphoid tissues, offering protection against enteric pathogens. Significance Group 3 innate lymphoid cells enriched in the gut mediate host resistance against intestinal pathogens. Their function and development can be regulated by diverse factors, including neuropeptides secreted by the enteric nervous system. We show that the neuropeptide vasoactive intestinal peptide (VIP) promotes the recruitment of these innate lymphoid cells and other immune cells to the gut through a receptor. Mice lacking VIP or its receptor were highly susceptible to an enteric pathogen infection. Replenishing the innate lymphoid cells or their secreted products into these mice was able to partially or fully restore host resistance to the infection. Thus, the enteric nervous system, through VIP, regulates the recruitment of innate lymphoid cells to the gut, offering protection against enteric pathogens.